📊 BMRN Key Takeaways
Investment Thesis
BioMarin demonstrates solid fundamental strength with 12.9% revenue growth, robust free cash flow generation of $725M (22.5% FCF margin), and exceptional financial health characterized by minimal leverage (0.10x Debt/Equity) and strong liquidity (5.21x current ratio). However, net income remained flat YoY despite revenue growth, and diluted EPS declined 18.6%, suggesting profitability pressures that warrant close monitoring.
BMRN Strengths
- Strong revenue growth of 12.9% YoY in competitive pharmaceutical sector
- Excellent cash generation with $725M free cash flow and 22.5% FCF margin indicating quality earnings
- Fortress balance sheet with $1.3B cash, minimal debt (0.10x Debt/Equity), and 5.21x current ratio providing strategic flexibility
- Exceptional interest coverage of 115.4x demonstrates zero financial distress risk
- Operating margin of 12.7% is healthy for specialty pharma business model
BMRN Risks
- Net income growth flat YoY despite 12.9% revenue growth signals margin compression and operational inefficiency
- Diluted EPS declined 18.6% YoY indicating share dilution or reduced per-share profitability despite revenue expansion
- Low return metrics (ROE 5.7%, ROA 4.6%) suggest capital is not being deployed efficiently despite strong balance sheet
- Elevated insider trading activity (16 Form 4 filings in 90 days) may indicate uncertainty or potential valuation concerns
- N/A gross margin data limits visibility into core product profitability and pricing power
Key Metrics to Watch
- Net margin trend - critical to understand if flat YoY net income is temporary or structural
- Operating expense growth relative to revenue growth to identify cost control issues
- Gross margin (once disclosed) to assess pricing power and manufacturing efficiency
- Free cash flow sustainability and capital allocation decisions to evaluate management's use of fortress balance sheet
- EPS trajectory and share dilution drivers to understand per-share value creation
BMRN Financial Metrics
💡 AI Analyst Insight
The 22.5% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 5.21x current ratio provides a solid financial cushion.
BMRN Profitability Ratios
BMRN vs Healthcare Sector
How BIOMARIN PHARMACEUTICAL INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BMRN Balance Sheet & Liquidity
BMRN 5-Year Financial Trend
5-Year Trend Summary: BIOMARIN PHARMACEUTICAL INC's revenue has grown significantly by 73% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.87 reflects profitable operations.
BMRN Growth Metrics (YoY)
BMRN Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $745.7M | -$30.7M | $-0.16 |
| Q2 2025 | $712.0M | $107.2M | $0.55 |
| Q1 2025 | $648.8M | $88.7M | $0.46 |
| Q3 2024 | $581.3M | $40.4M | $0.21 |
| Q2 2024 | $595.3M | $56.0M | $0.29 |
| Q1 2024 | $596.4M | $50.9M | $0.27 |
| Q3 2023 | $505.3M | -$6.7M | $-0.04 |
| Q2 2023 | $533.8M | $27.7M | $0.15 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BMRN Capital Allocation
BMRN SEC Filings
Access official SEC EDGAR filings for BIOMARIN PHARMACEUTICAL INC (CIK: 0001048477)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 19, 2026 | 4 | xslF345X06/wk-form4_1773953589.xml | View → |
| Mar 19, 2026 | 4 | xslF345X06/wk-form4_1773953452.xml | View → |
| Mar 19, 2026 | 4 | xslF345X06/wk-form4_1773953282.xml | View → |
| Mar 19, 2026 | 4 | xslF345X06/wk-form4_1773952468.xml | View → |
| Mar 18, 2026 | 4 | xslF345X06/wk-form4_1773855732.xml | View → |
❓ Frequently Asked Questions about BMRN
What is the AI rating for BMRN?
BIOMARIN PHARMACEUTICAL INC (BMRN) has an AI rating of BUY with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BMRN's key strengths?
Strong revenue growth of 12.9% YoY in competitive pharmaceutical sector. Excellent cash generation with $725M free cash flow and 22.5% FCF margin indicating quality earnings.
What are the risks of investing in BMRN?
Net income growth flat YoY despite 12.9% revenue growth signals margin compression and operational inefficiency. Diluted EPS declined 18.6% YoY indicating share dilution or reduced per-share profitability despite revenue expansion.
What is BMRN's revenue and growth?
BIOMARIN PHARMACEUTICAL INC reported revenue of $3.2B.
Does BMRN pay dividends?
BIOMARIN PHARMACEUTICAL INC does not currently pay dividends.
Where can I find BMRN SEC filings?
Official SEC filings for BIOMARIN PHARMACEUTICAL INC (CIK: 0001048477) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BMRN's EPS?
BIOMARIN PHARMACEUTICAL INC has a diluted EPS of $1.80.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.